和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02256 和誉-B

休市中 01-24 16:08:19

4.730

+0.030

+0.64%

最高4.780	最低4.680	成交量88.90万
今开4.680	昨收4.700	日振幅2.13%
总市值32.16亿	流通市值32.16亿	总股本6.80亿
成交额420.26万	换手率0.13%	流通股本6.80亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":4.73,"timestamp":1737706099013,"preClose":4.7,"halted":0,"volume":889000,"delay":0,"floatShares":680000000,"shares":680000000,"eps":-0.7168740459550808,"marketStatus":"休市中","change":0.03,"latestTime":"01-24 16:08:19","open":4.68,"high":4.78,"low":4.68,"amount":4202591,"amplitude":0.021277,"askPrice":4.73,"askSize":10000,"bidPrice":4.71,"bidSize":10000,"shortable":0,"etf":0,"ttmEps":-0.02707982277583951,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1737941400000},"marketStatusCode":7,"adr":0,"listingDate":1634054400000,"exchange":"SEHK","adjPreClose":4.7,"openAndCloseTimeList":[[1737682200000,1737691200000],[1737694800000,1737705600000]],"volumeRatio":0.7085404226129965,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256/","defaultTab":"news","newsList":[{"id":"2504944931","title":"【港股异动 | 和誉-B(02256.HK)盈喜后涨超3% 】和誉-B(02256.HK)盈喜后涨超3%，截至发稿，涨3.99%，报4.69港元，成交额579.22万港元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2504944931","media":"金融界","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504944931?lang=zh_cn&edition=full","pubTime":"2025-01-20 11:10","pubTimestamp":1737342658,"startTime":"0","endTime":"0","summary":"和誉-B(02256.HK)盈喜后涨超3%，截至发稿，涨3.99%，报4.69港元，成交额579.22万港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/20111047599243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2504446794","title":"港股异动 | 和誉-B(02256)盈喜后涨超3% 预期年度溢利不低于1000万元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2504446794","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504446794?lang=zh_cn&edition=full","pubTime":"2025-01-20 11:07","pubTimestamp":1737342445,"startTime":"0","endTime":"0","summary":"消息面上，和誉-B发布公告，预期本集团截至2024年12月31日止年度的总收入约为人民币5.04亿元，较截至2023年12月31日止年度的总收入约人民币1900万元增加约人民币4.85亿元；及截至2024年12月31日止年度的期内溢利不低于人民币1000万元，而截至2023年12月31日止年度的期内亏损约为人民币4.32亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1240141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2504444965","title":"和誉-B盘中异动 早盘快速拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504444965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504444965?lang=zh_cn&edition=full","pubTime":"2025-01-20 09:44","pubTimestamp":1737337445,"startTime":"0","endTime":"0","summary":"2025年01月20日早盘09时44分，和誉-B股票出现异动，股价大幅上涨5.10%。和誉-B股票所在的生物技术行业中，整体涨幅为0.71%。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。消息层面，截至09时44分，《和誉-B发盈喜 预期年度溢利不低于1000万元同比扭亏为盈》资讯为影响和誉-B的重要信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501200944059609a049&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501200944059609a049&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2504411276","title":"《盈喜》和誉(02256.HK)料去年扭亏为盈 赚至少1,000万人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2504411276","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504411276?lang=zh_cn&edition=full","pubTime":"2025-01-20 08:40","pubTimestamp":1737333600,"startTime":"0","endTime":"0","summary":"和誉发盈喜，预期去年总收入约为5.04亿元人民币(下同)，按年增加约4.85亿元；及溢利不低于1,000万元，而2023年亏损约为4.32亿元。过往派息公布日期派息事项派息内容2024/08/12中期业绩无派息2024/03/12末期业绩无派息2023/08/15中期业绩无派息2023/03/15末期业绩无派息公司指出，除了透过提高业务营运效率来改善成本控制外，预计去年总收入的增长及扭亏为盈亦主要归因于pimicotinib 的对外许可协议及与默克的首付款项7,000万美元，其对截至去年12月底止年度的收入作出重大贡献。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20211028115122107_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20211028115122107_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1411602/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2504411586","title":"和誉-B发盈喜 预期年度溢利不低于1000万元同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2504411586","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504411586?lang=zh_cn&edition=full","pubTime":"2025-01-20 08:28","pubTimestamp":1737332880,"startTime":"0","endTime":"0","summary":"　　和誉-B发布公告，预期本集团截至2024年12月31日止年度的总收入约为人民币5.04亿元，较截至2023年12月31日止年度的总收入约人民币1900万元增加约人民币4.85亿元；及截至2024年12月31日止年度的期内溢利不低于人民币1000万元，而截至2023年12月31日止年度的期内亏损约为人民币4.32亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-01-20/doc-inefqmne3773829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2504413073","title":"和誉-B(02256.HK)盈喜：预计2024年总收入达到人民币5.04亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504413073","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504413073?lang=zh_cn&edition=full","pubTime":"2025-01-20 07:03","pubTimestamp":1737327824,"startTime":"0","endTime":"0","summary":"格隆汇1月20日丨和誉-B发布公告，预期集团截至2024年12月31日止年度的总收入约为人民币5.04亿元，较截至2023年12月31日止年度的总收入约人民币1900万元增加约人民币4.85亿元；及截至2024年12月31日止年度的期内溢利不低于人民币1000万元，而截至2023年12月31日止年度的期内亏损约为人民币4.32亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/20070347594419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2503937121","title":"和誉-B盘中异动 股价大涨5.00%报4.410港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503937121","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503937121?lang=zh_cn&edition=full","pubTime":"2025-01-16 14:30","pubTimestamp":1737009011,"startTime":"0","endTime":"0","summary":"2025年01月16日下午盘14时30分，和誉-B股票出现异动，股价快速拉升5.00%。截至发稿，该股报4.410港元/股，成交量56.45万股，换手率0.08%，振幅4.52%。资金方面，该股资金流入92.755万港元，流出139.621万港元。和誉-B股票所在的生物技术行业中，整体涨幅为1.05%。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011614301198681639&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011614301198681639&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2501220683","title":"和誉-B1月7日收盘下跌1.28%，成交455.52万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501220683","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501220683?lang=zh_cn&edition=full","pubTime":"2025-01-07 17:02","pubTimestamp":1736240560,"startTime":"0","endTime":"0","summary":"1月7日，截至港股收盘，恒生指数下跌1.22%，报19447.58点。和誉-B收报4.61港元/股，下跌1.28%，成交量99.1万股，成交额455.52万港元，振幅3.0%。最近一个月来，和誉-B累计跌幅5.14%，今年来累计涨幅0.22%，跑赢恒生指数-3.05%的跌幅。财务数据显示，截至2024年6月30日，和誉-B实现营业总收入4.97亿元，同比增长2508.99%；归母净利润2.07亿元，同比增长199.14%；资产负债率5.32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107170542985dc831&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107170542985dc831&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2501221189","title":"和誉-B01月07日遭主力抛售94万元 环比增加184.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501221189","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501221189?lang=zh_cn&edition=full","pubTime":"2025-01-07 16:17","pubTimestamp":1736237825,"startTime":"0","endTime":"0","summary":"01月07日, 和誉-B股价跌1.28%，报收4.61元，成交金额455万元，换手率0.15%，振幅3.00%，量比0.50。和誉-B今日主力资金净流出94万元，连续5日净流出，上一交易日主力净流出33万元，今日环比增加184.85%。该股近5个交易日上涨2.45%，主力资金累计净流出489万元；近20日主力资金累计净流出603万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107161759a2188dd3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107161759a2188dd3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2501405411","title":"港股异动 | 和誉-B(02256)逆市涨超4% 依帕戈替尼相关临床获批 匹米替尼数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2501405411","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501405411?lang=zh_cn&edition=full","pubTime":"2025-01-06 15:11","pubTimestamp":1736147489,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B逆市涨超4%，截至发稿，涨4.48%，报4.66港元，成交额1104.74万港元。消息面上，和誉近期宣布，其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼已获中国国家药品监督管理局药品审评中心批准，开展治疗肝细胞癌的注册性临床研究。此外，公司近期公布匹米替尼CGVHD初步II期数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1233707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","02256","BK1161"],"gpt_icon":0},{"id":"2501742010","title":"和誉-B盘中异动 股价大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501742010","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501742010?lang=zh_cn&edition=full","pubTime":"2025-01-06 10:37","pubTimestamp":1736131022,"startTime":"0","endTime":"0","summary":"2025年01月06日早盘10时37分，和誉-B股票出现波动，股价急速拉升5.16%。和誉-B股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，和铂医药-B、云顶新耀-B、思路迪医药股份涨幅较大，振幅较大的相关个股有北海康成-B、和铂医药-B、来凯医药-B，振幅分别为22.31%、12.98%、10.56%。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010610370295f9cbc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010610370295f9cbc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2500616621","title":"和誉-B01月03日主力资金流出121万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2500616621","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500616621?lang=zh_cn&edition=full","pubTime":"2025-01-03 16:16","pubTimestamp":1735892183,"startTime":"0","endTime":"0","summary":"01月03日, 和誉-B股价涨1.13%，报收4.46元，成交金额728万元，换手率0.24%，振幅4.76%，量比1.02。和誉-B今日主力资金净流出121万元，连续3日净流出，上一交易日主力净流出205万元，今日环比减少40.98%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为70.00%，平均跌幅为2.35%。该股近5个交易日上涨3.24%，主力资金累计净流出310万元；近20日主力资金累计净流出300万元，其中净流出天数为7日。该股主力净额占比0.04%，港股市场排名2556/2656。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103161719ab9ceb55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103161719ab9ceb55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2500910803","title":"和誉-B（02256.HK）1月2日收盘下跌4.13%，成交1209.73万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500910803","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500910803?lang=zh_cn&edition=full","pubTime":"2025-01-02 17:14","pubTimestamp":1735809289,"startTime":"0","endTime":"0","summary":"1月2日，截至港股收盘，恒生指数下跌2.18%，报19623.32点。和誉-B收报4.41港元/股，下跌4.13%，成交量273.4万股，成交额1209.73万港元，振幅5.43%。最近一个月来，和誉-B累计跌幅7.16%，今年来累计跌幅4.13%，跑输恒生指数-2.18%的跌幅。财务数据显示，截至2024年6月30日，和誉-B实现营业总收入4.97亿元，同比增长2508.99%；归母净利润2.07亿元，同比增长199.14%；资产负债率5.32%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/02171447042859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2500119399","title":"和誉-B01月02日遭主力抛售205万元 环比增加439.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500119399","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500119399?lang=zh_cn&edition=full","pubTime":"2025-01-02 16:15","pubTimestamp":1735805720,"startTime":"0","endTime":"0","summary":"01月02日, 和誉-B股价跌4.13%，报收4.41元，成交金额1209万元，换手率0.40%，振幅5.43%，量比2.65。和誉-B今日主力资金净流出205万元，上一交易日主力净流出38万元，今日环比增加439.47%。该股近5个交易日上涨1.15%，主力资金累计净流出189万元；近20日主力资金累计净流出92万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102161534ab9b8109&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102161534ab9b8109&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2500991119","title":"和誉-B盘中异动 下午盘股价大跌5.00%报4.370港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500991119","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500991119?lang=zh_cn&edition=full","pubTime":"2025-01-02 13:27","pubTimestamp":1735795653,"startTime":"0","endTime":"0","summary":"2025年01月02日下午盘13时27分，和誉-B股票出现波动，股价大幅跳水5.00%。截至发稿，该股报4.370港元/股，成交量138.8万股，换手率0.20%，振幅5.00%。资金方面，该股资金流入136.613万港元，流出424.34万港元。和誉-B股票所在的生物技术行业中，整体跌幅为0.47%。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102132733ab9b4f40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102132733ab9b4f40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2492341153","title":"和誉-B：唐艳旻辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2492341153","media":"格隆汇资讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492341153?lang=zh_cn&edition=full","pubTime":"2024-12-20 19:36","pubTimestamp":1734694583,"startTime":"0","endTime":"0","summary":"格隆汇12月20日丨和誉-B(02256.HK)公告，于2024年12月20日，唐艳旻女士因其须付出更多精力处理其他工作提呈辞任非执行董事之职，自2024年12月20日起生效，辞任后不再担任公司任何职务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220193637a1fdae34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220193637a1fdae34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2492116911","title":"【券商聚焦】国元国际：和誉(02256)目前价值严重低估 长期看好其发展前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2492116911","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492116911?lang=zh_cn&edition=full","pubTime":"2024-12-19 13:46","pubTimestamp":1734587163,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国元国际发研指，和誉 宣布，其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼已获中国国家药品监督管理局药品审评中心批准，开展治疗肝细胞癌的注册性临床研究。目前，晚期肝癌病人缺乏有效的治疗方案。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1949962","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2492255339","title":"和誉-B(02256)上涨5.11%，报4.73元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492255339","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492255339?lang=zh_cn&edition=full","pubTime":"2024-12-18 11:38","pubTimestamp":1734493127,"startTime":"0","endTime":"0","summary":"12月18日，和誉-B(02256)盘中上涨5.11%，截至11:38，报4.73元/股，成交592.65万元。和誉开曼有限责任公司是一家专注于发现和开发创新小分子肿瘤治疗药物的生物制药公司，拥有十多个专注于精确肿瘤学和肿瘤免疫治疗的创新药物研发项目，其中五项已进入临床阶段。公司的主要战略方向是小分子肿瘤精准治疗、小分子肿瘤免疫治疗及其联合疗法的研究，以满足全球患者对癌症治疗的迫切需求。截至2024年中报，和誉-B营业总收入4.97亿元、净利润2.07亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/18113846524345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2492928113","title":"和誉-B盘中异动 临近午盘股价大涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492928113","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492928113?lang=zh_cn&edition=full","pubTime":"2024-12-18 11:38","pubTimestamp":1734493124,"startTime":"0","endTime":"0","summary":"2024年12月18日临近午盘11时38分，和誉-B股票出现异动，股价快速上涨5.11%。截至发稿，该股报4.730港元/股，成交量127.9万股，换手率0.19%，振幅6.89%。和誉-B股票所在的生物技术行业中，整体涨幅为0.23%。和誉-B公司简介：和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121811384495ea427d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121811384495ea427d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2492239940","title":"港股异动 | 和誉-B(02256)涨近4% 获CDE批准开展依帕戈替尼治疗肝细胞癌的注册性临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2492239940","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492239940?lang=zh_cn&edition=full","pubTime":"2024-12-18 11:23","pubTimestamp":1734492207,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B涨近4%，截至发稿，涨3.78%，报4.67港元，成交额537.73万港元。这项研究将作为支持依帕戈替尼上市的关键依据，也标志着依帕戈替尼在晚期或不可切除肝细胞癌治疗领域迈出了重要的一步。另外，12月8日，公司公告在第66届美国血液学会年会上口头报告了匹米替尼治疗2L+慢性移植物抗宿主病的初步II期研究结果。尽管大多数入组患者尚未完成cGvHD缓解评估所需要的6个月治疗周期，但匹米替尼20mg QD治疗患者的初步ORR已经达到64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CDE","BK1161","02256","BK4017","LU2488822045.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":0.0488},{"period":"1month","weight":0.0949},{"period":"3month","weight":0.1289},{"period":"6month","weight":0.5767},{"period":"1year","weight":0.8622},{"period":"ytd","weight":0.0283}],"compareEarnings":[{"period":"1week","weight":0.0246},{"period":"1month","weight":-0.0016},{"period":"3month","weight":-0.0254},{"period":"6month","weight":0.1789},{"period":"1year","weight":0.2377},{"period":"ytd","weight":0.0003}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司致力于发现及开发创新且差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK011是一种有效的高选择性小分子成纤维细胞生长因子受体4（FGFR4）抑制剂。ABSK091是一种分子靶向候选产品，是FGFR亚型1、2及3的高效及选择性抑制剂。该公司的产品主要用于治疗肝细胞癌（HCC）、尿路上皮癌（UC）及胃癌（GC）。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.147902},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.021578},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.062878},{"month":4,"riseRate":0.333333,"avgChangeRate":0.018452},{"month":5,"riseRate":0,"avgChangeRate":-0.043841},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.013147},{"month":7,"riseRate":0.666667,"avgChangeRate":0.049332},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.050943},{"month":9,"riseRate":0.666667,"avgChangeRate":0.042883},{"month":10,"riseRate":0.666667,"avgChangeRate":0.004984},{"month":11,"riseRate":0.75,"avgChangeRate":0.204437},{"month":12,"riseRate":0,"avgChangeRate":-0.093315}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}